Pila Pharma AB (OSTO:PILA) Other Current Liabilities: kr1.34 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:PILA Pila Pharma AB OSTO:PILA
49 GF Score
Price kr1.31
GF Value kr1.82
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pila Pharma AB Other Current Liabilities?

Pila Pharma AB OSTO:PILA +2.34% 49 Other Current Liabilities is kr1.34 Mil as of Dec. 2025. GuruFocus rates OSTO:PILA with a GF Score™ of 49/100 and a GF Value™ of kr1.82 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Pila Pharma AB's other current liabilities for the quarter that ended in Dec. 2025 was kr1.34 Mil.

Pila Pharma AB's quarterly other current liabilities increased from Dec. 2024 (kr0.52 Mil) to Jun. 2025 (kr2.18 Mil) but then declined from Jun. 2025 (kr2.18 Mil) to Dec. 2025 (kr1.34 Mil).

Pila Pharma AB's annual other current liabilities increased from Dec. 2023 (kr0.49 Mil) to Dec. 2024 (kr0.52 Mil) and increased from Dec. 2024 (kr0.52 Mil) to Dec. 2025 (kr1.34 Mil).

Pila Pharma AB Other Current Liabilities Related Terms

Pila Pharma AB Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pila Pharma AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pila Pharma AB Other Current Liabilities Chart

Pila Pharma AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 1.12 0.88 0.49 0.52 1.34

Pila Pharma AB Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.73 0.52 2.18 1.34
OSTO:PILA
49GF Score
Pila Pharma AB OSTO:PILA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pila Pharma AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of kr1.34 Mil mean?
Pila Pharma AB (OSTO:PILA) has a Other Current Liabilities of kr1.34 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pila Pharma AB.
Is Pila Pharma AB's Other Current Liabilities too high?
Pila Pharma AB's current Other Current Liabilities is kr1.34 Mil. Overall, Pila Pharma AB has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pila Pharma AB's Other Current Liabilities compare to VRTX and REGN?
Pila Pharma AB's Other Current Liabilities of kr1.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pila Pharma AB. Pila Pharma AB's current Other Current Liabilities is kr1.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pila Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Pila Pharma AB (OSTO:PILA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.82, compared to a current price of kr1.31 — trading 28% below its estimated fair value. The current Other Current Liabilities is kr1.34 Mil. Pila Pharma AB's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Pila Pharma AB (OSTO:PILA), the current Other Current Liabilities is kr1.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pila Pharma AB (OSTO:PILA) Overvalued in 2026?

Based on GuruFocus' analysis, Pila Pharma AB stock appears to be undervalued. The current stock price of kr1.31 is trading 28% below its estimated GF Value™ of kr1.82. GuruFocus considers Pila Pharma AB to be Modestly Undervalued.

Key valuation signals for OSTO:PILA:

  • Other Current Liabilities: kr1.34 Mil
  • GF Value™: kr1.82 vs. price of kr1.31 (28% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the OSTO:PILA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pila Pharma AB Business Description

Address Norra Vallgatan 72, Malmo, SWE, 211 21
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
49GF Score

Get the complete analysis for OSTO:PILA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.31
Price
kr1.82
GF Value